Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Galapagos   /   Galapagos 100 euro per aandeel

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,920   +0,160   (+0,62%) Dagrange 25,840 - 26,160 30.781   Gem. (3M) 88,9K

Galapagos 100 euro per aandeel

Volgen
1.208 Posts
Pagina: «« 1 ... 27 28 29 30 31 ... 61 »» | Laatste | Omlaag ↓
  1. [verwijderd] 18 juni 2017 18:22
    Hoe snel gaat koers Galapagos naar 100 euro ?

    5 Answers to Questions Gilead Sciences' Investors Probably Have
    Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.

    Keith Speights (TMFFishBiz) Jun 18, 2017 at 11:42AM

    3. What are the prospects for filgotinib?
    The FDA stunned Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) by not approving JAK inhibitor baricitinib for treating rheumatoid arthritis. What does Gilead make of the situation, since the biotech has its own JAK inhibitor, filgotinib, in phase 3 testing for rheumatoid arthritis as well as Crohn's disease and ulcerative colitis?

    Bischofberger said that he has "no insights beyond what was published" regarding the FDA decision. However, he noted that Gilead first approached the FDA about conducting a study with only one dose, but the FDA pushed the company to use two doses. He now wonders if perhaps the FDA knew something about baricitinib then, since the agency requested more clinical data from Lilly and Incyte for determining the appropriate doses.

    Filgotinib, which Gilead licensed from Galapagos (NASDAQ: GLPG), now has 1,700 patient-years of safety data, according to Bischofberger. It was the safety data that Galapagos presented from phase 2 studies that was really attractive to Gilead. He added that he feels "very confident that this compound will make it through" to the approval proces

    www.fool.com/investing/2017/06/18/5-a...
  2. [verwijderd] 18 juni 2017 19:20
    quote:

    inspirator schreef op 18 juni 2017 18:22:

    Hoe snel gaat koers Galapagos naar 100 euro ?

    5 Answers to Questions Gilead Sciences' Investors Probably Have
    Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.

    Keith Speights (TMFFishBiz) Jun 18, 2017 at 11:42AM

    3. What are the prospects for filgotinib?
    The FDA stunned Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) by not approving JAK inhibitor baricitinib for treating rheumatoid arthritis. What does Gilead make of the situation, since the biotech has its own JAK inhibitor, filgotinib, in phase 3 testing for rheumatoid arthritis as well as Crohn's disease and ulcerative colitis?

    Bischofberger said that he has "no insights beyond what was published" regarding the FDA decision. However, he noted that Gilead first approached the FDA about conducting a study with only one dose, but the FDA pushed the company to use two doses. He now wonders if perhaps the FDA knew something about baricitinib then, since the agency requested more clinical data from Lilly and Incyte for determining the appropriate doses.

    Filgotinib, which Gilead licensed from Galapagos (NASDAQ: GLPG), now has 1,700 patient-years of safety data, according to Bischofberger. It was the safety data that Galapagos presented from phase 2 studies that was really attractive to Gilead. He added that he feels "very confident that this compound will make it through" to the approval proces

    www.fool.com/investing/2017/06/18/5-a...
    Snel
  5. [verwijderd] 18 juni 2017 23:17
    quote:

    inspirator schreef op 18 juni 2017 18:22:

    Hoe snel gaat koers Galapagos naar 100 euro ?

    5 Answers to Questions Gilead Sciences' Investors Probably Have
    Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.

    Keith Speights (TMFFishBiz) Jun 18, 2017 at 11:42AM

    3. What are the prospects for filgotinib?
    The FDA stunned Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) by not approving JAK inhibitor baricitinib for treating rheumatoid arthritis. What does Gilead make of the situation, since the biotech has its own JAK inhibitor, filgotinib, in phase 3 testing for rheumatoid arthritis as well as Crohn's disease and ulcerative colitis?

    Bischofberger said that he has "no insights beyond what was published" regarding the FDA decision. However, he noted that Gilead first approached the FDA about conducting a study with only one dose, but the FDA pushed the company to use two doses. He now wonders if perhaps the FDA knew something about baricitinib then, since the agency requested more clinical data from Lilly and Incyte for determining the appropriate doses.

    Filgotinib, which Gilead licensed from Galapagos (NASDAQ: GLPG), now has 1,700 patient-years of safety data, according to Bischofberger. It was the safety data that Galapagos presented from phase 2 studies that was really attractive to Gilead. He added that he feels "very confident that this compound will make it through" to the approval proces

    www.fool.com/investing/2017/06/18/5-a...
    Galapagos
    Aan het bedrijvenfront is de agenda vrijwel leeg. Het wachten is op het begin van de halfjaarcijferperiode.

    Van de in Amsterdam genoteerde bedrijven praat biotechnologiebedrijf Galapagos beleggers dinsdag bij over de jongste wetenschappelijke ontwikkelingen.
  8. [verwijderd] 19 juni 2017 19:31
    quote:

    inspirator schreef op 18 juni 2017 18:22:

    Hoe snel gaat koers Galapagos naar 100 euro ?

    5 Answers to Questions Gilead Sciences' Investors Probably Have
    Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.

    Keith Speights (TMFFishBiz) Jun 18, 2017 at 11:42AM

    3. What are the prospects for filgotinib?
    The FDA stunned Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) by not approving JAK inhibitor baricitinib for treating rheumatoid arthritis. What does Gilead make of the situation, since the biotech has its own JAK inhibitor, filgotinib, in phase 3 testing for rheumatoid arthritis as well as Crohn's disease and ulcerative colitis?

    Bischofberger said that he has "no insights beyond what was published" regarding the FDA decision. However, he noted that Gilead first approached the FDA about conducting a study with only one dose, but the FDA pushed the company to use two doses. He now wonders if perhaps the FDA knew something about baricitinib then, since the agency requested more clinical data from Lilly and Incyte for determining the appropriate doses.

    Filgotinib, which Gilead licensed from Galapagos (NASDAQ: GLPG), now has 1,700 patient-years of safety data, according to Bischofberger. It was the safety data that Galapagos presented from phase 2 studies that was really attractive to Gilead. He added that he feels "very confident that this compound will make it through" to the approval proces

    www.fool.com/investing/2017/06/18/5-a...
    Als morgenmiddag na 14.00 uur koers Galapagos boven 100 euro staat, is het nog sneller als verwacht.
  9. [verwijderd] 20 juni 2017 00:20
    Another JAK1 inhibitor, filgotinib, has been reported to be superior to placebo in inducing remission in patients with moderate to severe Crohn’s disease

    Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

    www.bmj.com/content/357/bmj.j2505
  10. [verwijderd] 20 juni 2017 00:24
    Waardering Galapagos meer als 100 euro:

    BTIG initiates coverage on Galapagos NV (NASDAQ: GLPG ) with a Buy rating and a price target of $98.00.

    Analyst Dane Leone says the investment will improve as clinical development outcomes over the next 12 months come to fruition. Leone gives three reasons for the bullish new coverage:

    filgotinib is the main revenue driver of our model, and has demonstrated potential to be a best in class JAK inhibitor, but is also facing fierce competition for auto immune disorders;

  11. [verwijderd] 20 juni 2017 07:48
    Galapagos' R&D Update 2017: rapidly advancing our product candidates
    Tuesday, June 20, 2017 5:32 AM UTC 0 comments
    Filgotinib
    Darwin 3: improved activity, consistent safety parameters for filgotinib
    Ph2 studies initiated in 6 new indications
    Cystic fibrosis
    Three different triple combos in development
    Successful completion of Ph1 with three individual combo components
    Start of regulatory process next month, patient study with first triple combo expected to begin in Q4 '17 in Europe
    Topline data for GLPG1690 in IPF in Q3 '17
    Opening of US IND and dosing of first osteoarthritis patient in Phase 1b trial with GLPG1972
    Growing number of clinical stage proprietary programs in fibrosis, psoriasis, and other indications

    www.econotimes.com/Galapagos-RD-Updat...
  14. B...K 20 juni 2017 07:58
    Tevreden geluid bij Galapagos
    Topman te spreken over voortgang.

    (ABM FN-Dow Jones) Galapagos zal dinsdag in New York een positief geluid laten horen tijdens de jaarlijkse R&D update. Dit bleek dinsdag voorbeurs uit een persbericht van het Belgisch-Nederlandse biotechbedrijf.

    "Ik ben zeer tevreden over de executie van de strategie door onze teams; dit heeft geleid tot grote mogelijkheden voor ons bedrijf", zei CEO Onno van de Stolpe.

    Galapagos heeft volgens de topman "nu een sterke pijplijn met meerdere kandidaatmedicijnen in verschillende ziektegebieden."

    Galapagos heeft vijf klinische producten in volledig eigendom en beschikt over de kasreserves voor de verdere zelfstandige klinische ontwikkeling, stelde CEO Van de Stolpe.

    Met betrekking tot filgotinib meldde Galapagos dat uit de Darwin 3 studie een verbeterde activiteit en consistente veiligheidsparameters bleek.Filgotinib wordt op dit moment getest in drie Fase 3 en zes bijkomende Fase 2 proof-of-concept studies.

    Rondom Cystic fibrosis heeft Galapagos drie verschillende 'triple combo's' in ontwikkeling. Gunstige ontwikkelingen en een regelgevende review die volgende maand start, zouden een patiëntenstudie met '2737 in combinatie met Orkambi en een patiëntenstudie met de eerste triple combo in het vierde kwartaal van 2017 mogelijk moeten maken.Daarnaast verwacht Galapagos in 2018 twee triple combinatiestudies te starten.

    Later dit jaar verwacht Galapagos resultaten met MOR106, een antilichaam gericht op IL-17C in een Fase 1b studie in patiënten met atopische dermatitis. Daarnaast verwacht Galapagos ook later dit jaar een nieuwe studie te kunnen starten met GPR84-remmer GLPG1205 in een nieuwe indicatie.

    Het aandeel Galapagos sloot maandag maar liefst 4,0 procent hoger op 72,79 euro.

    Door: ABM Financial News.

    info@abmfn.nl

    Redactie: +31(0)20 26 28 999

    Copyright ABM Financial News. All rights reserved

    (END) Dow Jones Newswires

    June 20, 2017 01:48 ET (05:48 GMT)
1.208 Posts
Pagina: «« 1 ... 27 28 29 30 31 ... 61 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Galapagos meldt fraai succes rond nieuwe therapie: zit er weer muziek in het aandeel?

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. Galapagos: bemoedigende nieuwe resultaten met recidief/refractair non-Hodgkin lymfoom
  2. Kepler Cheuvreux zet Galapagos op verkooplijst
  3. Klinische resultaten Galapagos steunen celtherapie-hypothese
  4. Deutsche Bank verlaagt koersdoel Galapagos
  5. Financials en Shell doen goede zaken op terughoudend Damrak
  6. Galapagos herhaalt cash burn voor 2024
  7. Galapagos benoemt investeerder Nodelman in bestuur
  8. EcoR1 nog groter in Galapagos
  9. EcoR1 groter in Galapagos
  10. FMR LLC kleiner in Galapagos